11-64807010-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001370259.2(MEN1):c.912+1G>A variant causes a splice donor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001370259.2 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
- multiple endocrine neoplasia type 1Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), G2P, ClinGen, Orphanet, Ambry Genetics
- familial isolated hyperparathyroidismInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- pituitary gigantismInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary pheochromocytoma-paragangliomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MEN1 | NM_001370259.2 | c.912+1G>A | splice_donor_variant, intron_variant | Intron 6 of 9 | ENST00000450708.7 | NP_001357188.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia, type 1 Pathogenic:3
This variant is considered pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. mRNA analysis has demonstrated abnormal mRNA splicing occurs [PMID: 18753104, 10090472]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 18753104, 10090472, 34183184, 39112918]. -
Variant summary: MEN1 c.912+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. Experimental evidence supports these predictions demonstrating that this variant affects mRNA splicing, leading to deletion of exon 6 in the MEN1 transcript and resulting in a frameshift and a premature stop codon (Mutch_ 1999 and Alzahrani_2008). The variant was absent in 250826 control chromosomes (gnomAD). c.912+1G>A has been reported in the literature in multiple individuals affected with Multiple Endocrine Neoplasia Type 1 (examples: Mutch_ 1999 and Alzahrani_2008). These data indicate that the variant is very likely to be associated with disease. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
This sequence change affects a donor splice site in intron 6 of the MEN1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MEN1 are known to be pathogenic (PMID: 12112656, 17853334). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with clinical features of multiple endocrine neoplasia type 1 (PMID: 10090472, 18753104). ClinVar contains an entry for this variant (Variation ID: 96254). Studies have shown that disruption of this splice site is associated with inconclusive levels of altered splicing (Invitae). For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:2
- -
The c.912+1 G>A splice site variant in the MEN1 gene has been previously reported in association with multiple endocrine neoplasia type 1 (MEN1) (Mutch et al., 1999). This variant destroys the canonical splice donor site in intron 6, and is expected to cause abnormal gene splicing. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.912+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 5 of the MEN1 gene. This mutation was detected in an individual with a confirmed diagnosis of multiple endocrine neoplasia type 1 (Mutch MG, et al. Hum. Mutat. 1999;13(3):175-85). In addition, this mutation was detected in 16 year old female with Cushing syndrome attributable to a cortisol-producing adrenal adenoma, hyperparathyroidism, and pituitary microprolactionma. RNA studies confirmed that this mutation causes skipping of exon 6 in the MEN1 transcript, a shift in reading frame, and a premature stop codon 64 amino acids downstream (Alzahrani AS, et al. Endocr Pract;14(5):595-602). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the information presented in the literature, since mutations that disrupt the canonical splice donor site are typically deleterious in nature, this alteration is interpreted as a disease causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at